About all

Ic autoimmune: Interstitial cystitis (IC) • AARDA

Содержание

Interstitial Cystitis and the Autoimmune Connection – Naturopathic Doctor News and Review

Arlene B. Donar, ND

Interstitial cystitis (IC) is a chronic, debilitating, multifactorial syndrome characterized by excessive urgency and frequency of urination, suprapubic pain, dyspareunia and pelvic pain along with negative urine cultures. The course of the disease is usually marked by flare-ups and remissions. IC generally persists throughout the patient’s life. On clinical evaluation, patients presenting with IC should have no other definable pathology such as urinary infections, carcinoma or radiation-induced cystitis (Metts, 2001). This symptom complex has also been referred to as painful bladder syndrome, leaky bladder syndrome and irritative bladder syndrome (Marshall, 2003).

According to a 2001 Nurses’ Health Study, IC may affect as many as 700,000 women in the U.S., suggesting that the prevalence among women may be as high as 67 per 100,000. Women comprise up to 90% of patients with IC. Onset usually occurs between the ages of 30 and 70 years of age with a median age of 43 (Metts, 2001).

Most patients will consult at least five physicians, including psychiatrists, over a period of more than four years before IC is diagnosed (Metts, 2001).

Etiology

While the exact cause of IC is not known, it is most likely related to autoimmune and allergic etiologies. Numerous studies have demonstrated that symptoms originate from a defect in the glycosaminoglycan (GAG) component of the layer of mucin that covers and protects the bladder urothelium. This breakdown of the bladder protective layer leads to a hyperpermeable bladder wall, stimulation of pain receptors and inflammatory symptoms (Marshall, 2003).

Stress is also known to contribute to symptoms. Patients may report vasodilation, flushing and itching and general skin hypersensitivity in the genital area, upper thighs and abdomen. Corticotrophin-releasing hormone (CRH) secreted from non-CNS sites has proinflammatory actions that may be mediated via mast cell activation. Mast cells are also involved in autoimmunity (Sant et al., 2007). Mastocytosis has been reported in the bladders of 30%-65% of patients with IC. Further evidence of mast cell involvement comes from increased levels of histamine in bladder wall epithelium in IC patients (Marshall, 2003).

IC has the classic picture of autoimmune disease: symptom chronicity with exacerbations and remissions, organ-specific and non-organ-specific mononuclear cell infiltrates, the lack of a clearly defined pathogen and response to steroids or other immunosuppressants (Metts, 2001).

Autoimmune Connection

IC was first reported in 1915 when GL Hunner described two patients with “a rare type of bladder ulcer in women.” Researcher G.M. Fister, MD was among the first to demonstrate a link between autoimmune disease and IC in a patient with systemic lupus erythematosus (SLE). He suggested that patients with IC shared a clinical picture with autoimmune connective tissue disease (Fister, 1938). A 1983 study by Orth et al. confirmed Fister’s findings, and the term “lupus cystitis” was introduced (Orth et al., 1983). Histologically, no immune deposits of IgG, IgA, IgM or complement C1q were found in the mucosa and perivascular regions of urinary bladder specimens (Shibata et al., 2004).

Silk (1970) reported that he had found bladder-specific antibodies in IC patients. His findings indicated that IC belonged to the group of organ-specific autoimmune diseases (Silk, 1970). In a separate 1972 study by Jokinen et al., 31 of 33 (94%) patients with IC were found to have tissue autoantibodies against both non-organ-specific and organ-specific antigens.

On the basis of their findings, they stated that it seems probable that IC “belongs to the group of autoimmune diseases that lies between organ-specific and non-organ-specific systemic diseases. The disease is confined to one organ, but the tissue antibodies are non-organ-specific” (Jokinen et al., 1972).

A familial predisposition to IC was proposed after a report of IC in monozygotic female twins and a mother and daughter (Oravisto, 1980). A study by Christmas and Bottazzo demonstrated that IC is associated with HLA-DR6, and the allele seems to convey a relative risk factor of 4.91. There was evidence of HLA class I inappropriate hyperexpression in the urothelial cells; however, the most striking difference between the bladder tissue of IC patients and the normal control group was that the expression of HLA-DR molecules in the urothelium cells was positive for all three antibodies used in the study. In addition, large numbers of infiltrating cells expressing HLA class II CD3+T cells were evident within the submucosa. This class II expression along with class I hyperexpression in the urothelial cells allows them to activate CD4+ and CD8+ lymphocytes, which appear to be the main effector in the mechanism in destruction of the urothelial cells in IC (Christmas and Bottazzo, 1992).

Naturopathic Treatment

When considering an autoimmune etiology, an effective approach to treatment must address symptom relief, tissue repair and immune function.

  • Nutrition       Dietary modification is the cornerstone of IC therapy. Between 53%-63% of IC patients can identify foods that exacerbate symptoms or cause a flare-up. High acidic foods such as alcoholic beverages, carbonated drinks, caffeine, spicy foods, tomatoes, vinegar, chocolate and citrus fruits are among the worst offenders. Arylalkylamines (tryptophan, tyrosine, phenylalanine and tyramine) have also been implicated as triggers, particularly those found in bananas, beer, mayonnaise, nuts, onions, raisins and yogurt (Marshall, 2003). Acid or potassium is often the suspected mechanism (Hudson, 2001). Since the response to these foods is highly variable, an elimination/challenge is quite useful to identify individual triggers. Essential fatty acids in the form of fish oil or flaxseed oil should be included, along with buffered vitamin C (non-citrus source) as both antioxidants and mast cell stabilizers. Pro-inflammatory saturated fats should be greatly reduced or eliminated from the diet, with a focus on anti-inflammatory fruits and vegetables tolerable by the patient.
  • Herbal Supplementation Anti-inflammatory and anti-oxidative supplementation is essential in an autoimmune protocol. Botanicals to consider either in capsule or tincture form include, but are not limited to: Boswellia, Curcuma longa, Glycyrrhiza glabra, Camellia sinensis, pycnogenol, Vitis vinifera L. Quercetin should also be included as a mast cell stabilizer.

Botanical methyl donors such as onion and garlic have an anti-inflammatory and analgesic effect on damaged mucosal lining (Hudson, 2001) – again, only if tolerable by the patient.

Other herbs to consider are: 1) Those in the demulcent family for their ability to protect and soothe the damaged mucosal lining, such as Ulmus rubra, Althaea officinalis, Avena sativa, Symphytum officinale or Zea mays; and 2) anti-spasmodics for pain relief, including Viburnum opulus, Dioscorea villosa and Piscidia piscipula.

  • Immune System Modulation of the immune system must be addressed when considering an autoimmune etiology. Plant sterols and sterolins in a ratio of 200:1 (beta-sitosterol:beta-sitosterolin) can selectively enhance the activity of T-helper 1 cells (Th-1) while leaving unchanged or inhibiting the T-helper 2 cells (Th-2). The stimulation of the Th-1 pathway leads to the destruction of inflammatory cells and a reduction in the resulting Th-2 mediated cytokines. Plant sterols can also maintain cortisol levels while elevating DHEA, thereby decreasing the cortisol:DHEA ratio and buffering a negative stress response (Bouic et al., 1996).

Proteolytic enzymes taken on an empty stomach provide a dual function in their ability to balance the immune system and act as a potent anti-inflammatory.

Patients should be willing to commit to a treatment program of a minimum of 3-6 months, with some level of symptom relief within the early stages of their protocol. An autoimmune approach to treatment must address inflammation, oxidative damage as well as modulation of the immune system. Therapy specific to IC includes healing of the bladder wall, histamine inhibition and anti-spasmodics for pain relief.


Arlene B. Donar, ND earned her naturopathic degree from the University of Bridgeport College of Naturopathic Medicine. She is board certified and licensed as an ND in Connecticut. Dr. Donar also holds a Master of Arts degree in speech and language pathology, and has worked as both a private consultant and adjunct professor in speech communications. Dr. Donar is the former medical director of the supplement manufacturer Heartguardian. She maintains a private practice in Manhattan, working primarily with clients with chronic health conditions, and lectures locally on prevention and treatment of disease using botanical medicine and clinical nutrition.

References

Metts JF: Interstitial cystitis: urgency and frequency syndrome, Am Fam Physician 64:1199-206, 2001.

Marshall K: Interstitial cystitis: understanding the syndrome, Altern Med Rev 8(4):426-437, 2003.

Sant GR et al: The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis, Urology 69(4 Suppl):S34-S40, 2007.

Fister GM: Similarity of interstitial cystitis (Hunner’s Ulcer) to lupus erythematosus, J Urol (40):37-41, 1938.

Orth RW et al: Lupus cystitis: primary bladder manifestations of systemic lupus erythematosus, Ann Intern Med 98(3):323-6, 1983.

Shibata S et al: Severe interstitial cystitis associated with Sjogren’s syndrome, Intern Med 43:248-252, 2004.

Silk MR: Bladder antibodies in interstitial cystitis, J Urol 103(3):307-309, 1970.

Jokinen EJ et al: Antitissue antibodies in interstitial cystitis, Clin Exp Immunol 11:333-339, 1972.

Oravisto KJ: Interstitial cystitis as an autoimmune disease, a review, Eur Urol 6:10-13, 1980.

Christmas TJ, Bottazzo GF: Abnormal urothelial HLA-DR expression in interstitial cystitis, Clin Exp Immunol 87:450-454, 1992.

Hudson T: Interstitial cystitis: a new approach, Townsend Letter 211:172-173, 2001.

Bouic PJ et al: Beta-sitosterol and beta-sitosterol glucoside stimulate human peripheral blood lymphocyte proliferation: implications for their use as an immunomodulary vitamin combination, Int J Immunopharmacol 18:693-700, 1996.

Advertisements

Interstitial cystitis and systemic autoimmune diseases

  • 1

    Nordling J et al. (2004) Primary evaluation of patients suspected of having interstitial cystitis (IC). Eur Urol 45: 662–669

    CAS 
    Article 

    Google Scholar 

  • 2

    Erickson DR et al. (2001) Nonbladder related symptoms in patients with interstitial cystitis. J Urol 166: 557–561

    CAS 
    Article 

    Google Scholar 

  • 3

    Ito T et al. (2000) Interstitial cystitis in Japan. BJU Int 86: 634–637

    CAS 
    Article 

    Google Scholar 

  • 4

    Curhan GC et al. (1999) Epidemiology of interstitial cystitis: a population based study. J Urol 161: 549–552

    CAS 
    Article 

    Google Scholar 

  • 5

    Rosenberg MT and Hazzard M (2005) Prevalence of interstitial cystitis symptoms in women: a population based study in the primary care office. J Urol 174: 2231–2234

    Article 

    Google Scholar 

  • 6

    Leppilahti M et al. (2005) Prevalence of clinically confirmed interstitial cystitis in women: a population based study in Finland. J Urol 174: 581–583

    Article 

    Google Scholar 

  • 7

    Temml C et al. (2006) Prevalence and correlates for interstitial cystitis symptoms in women participating in a health screening project. Eur Urol 51: 803–808

    Article 

    Google Scholar 

  • 8

    Propert KJ et al. (2000) A prospective study of interstitial cystitis: results of longitudinal followup of the interstitial cystitis data base cohort. The Interstitial Cystitis Data Base Study Group. J Urol 163: 1434–1439

    CAS 
    Article 

    Google Scholar 

  • 9

    Jones CA et al. (1994) Prevalence of interstitial cystitis in the United States. J Urol 151: 423A

    Article 

    Google Scholar 

  • 10

    Abrams P et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167–178

    Article 

    Google Scholar 

  • 11

    Oberpenning F et al. (2002) Interstitial cystitis: an update. Curr Opin Urol 12: 321–332

    Article 

    Google Scholar 

  • 12

    Van de Merwe JP et al. (1993) Sjögren’s syndrome in patients with interstitial cystitis. J Rheumatol 20: 962–966

    CAS 
    PubMed 

    Google Scholar 

  • 13

    Van de Merwe JP (2003) Sjögren’s syndrome in patients with interstitial cystitis. Preliminary results in 100 patients. Int J Urol 10 (Suppl): S69

    Google Scholar 

  • 14

    Alagiri M et al. (1997) Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology 49 (5A Suppl): S52–S57

    Article 

    Google Scholar 

  • 15

    Yamada T (2003) Significance of complications of allergic diseases in young patients with interstitial cystitis. Int J Urol (10 Suppl): S56–S58

    Article 

    Google Scholar 

  • 16

    Peeker R et al. (2003) Intercurrent autoimmune conditions in classic and non-ulcer interstitial cystitis. Scand J Urol Nephrol 37: 60–63

    Article 

    Google Scholar 

  • 17

    Ochs RL and Tan EM (1997) Autoimmunity and interstitial cystitis. In Interstitial Cystitis, 47–52 (Ed. Sant GR) Philadelphia: Lippincott-Raven

    Google Scholar 

  • 18

    Ochs RL et al. (1994) Autoantibodies in interstitial cystitis. J Urol 151: 587–592

    CAS 
    Article 

    Google Scholar 

  • 19

    Keay S et al. (1997) Urine autoantibodies in interstitial cystitis. J Urol 157: 1083–1087

    CAS 
    Article 

    Google Scholar 

  • 20

    Danchenko N et al. (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15: 308–318

    CAS 
    Article 

    Google Scholar 

  • 21

    Alarçon-Segovia D et al. (1984) Involvement of the urinary bladder in systemic lupus erythematosus. A pathologic study. J Rheumatol 11: 208–210

    PubMed 

    Google Scholar 

  • 22

    Grennan DM et al. (1977) Sjögren’s syndrome in SLE: Part 2. An examination of the clinical significance of Sjögren’s syndrome by comparison of its frequency in typical and atypical forms of SLE, overlap syndromes and scleroderma. N Z Med J 86: 376–379

    CAS 
    PubMed 

    Google Scholar 

  • 23

    Andonopoulos AP et al. (1990) Sjögren’s syndrome in systemic lupus erythematosus. J Rheumatol 17: 201–204

    CAS 
    PubMed 

    Google Scholar 

  • 24

    Gilboe IM et al. (2001) Sicca symptoms and secondary Sjögren’s syndrome in systemic lupus erythematosus: comparison with rheumatoid arthritis and correlation with disease variables. Ann Rheum Dis 60: 1103–1109

    CAS 
    Article 

    Google Scholar 

  • 25

    Drosos AA et al. (1990) Subacute cutaneous lupus erythematosus in Greece. A clinical, serological and genetic study. Ann Med Interne (Paris) 141: 421–424

    CAS 

    Google Scholar 

  • 26

    Chen MY et al. (2004) Is there an ethnic difference in the prevalence of lupus cystitis? A report of six cases. Lupus 13: 263–269

    Article 

    Google Scholar 

  • 27

    Vercammen M et al. (2007) Diagnostic accuracy of the FIDIS multiplex fluorescent microsphere immunodetection system for anti-extractable nuclear antigen (ENA) antibodies in connective tissue diseases. Clin Chem Lab Med 45: 505–512

    CAS 
    Article 

    Google Scholar 

  • 28

    Sauerland U et al. (2005) Clinical utility of the anti-CCP assay: experiences with 700 patients. Ann NY Acad Sci 1050: 314–318

    CAS 
    Article 

    Google Scholar 

  • 29

    Van Noord C et al. (2005) Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjögren’s syndrome. Ann Rheum Dis 64: 160–162

    CAS 
    Article 

    Google Scholar 

  • 30

    Cohen MG and Webb J (1987) Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis 46: 853–858

    CAS 
    Article 

    Google Scholar 

  • 31

    Alarçon-Segovia D et al. (2005) Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 52: 1138–1147

    Article 

    Google Scholar 

  • 32

    Andonopoulos AP et al. (1987) Secondary Sjogren’s syndrome in rheumatoid arthritis. J Rheumatol 14: 1098–1103

    CAS 
    PubMed 

    Google Scholar 

  • 33

    Lee KL et al. (2006) Lower urinary tract symptoms in female patients with rheumatoid arthritis. Scand J Rheumatol 35: 96–101

    Article 

    Google Scholar 

  • 34

    Fox RI et al. (1984) Primary Sjögren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 14: 77–105

    CAS 
    Article 

    Google Scholar 

  • 35

    Asherson RA et al. (1992) Antiphospholipid antibodies and HLA associations in primary Sjögren’s syndrome. Ann Rheum Dis 51: 495–498

    CAS 
    Article 

    Google Scholar 

  • 36

    Yasuda S et al. (2004) Abacterial prostatitis and primary biliary cirrhosis with Sjögren’s syndrome. Mod Rheumatol 14: 70–72

    Article 

    Google Scholar 

  • 37

    Ramos-Casals M et al. (2006) Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum 35: 312–321

    CAS 
    Article 

    Google Scholar 

  • 38

    Fox RI et al. (2001) Use of muscarinic agonists in the treatment of Sjögren’s syndrome. Clin Immunol 101: 249–263

    CAS 
    Article 

    Google Scholar 

  • 39

    Robinson CP et al. (1998) Transfer of human serum IgG to nonobese diabetic Igµnull mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren’s syndrome. Proc Natl Acad Sci USA 95: 7538–7543

    CAS 
    Article 

    Google Scholar 

  • 40

    Bacman S et al. (1998) Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren’s syndrome. Invest Ophthalmol Vis Sci 39: 151–156

    CAS 
    PubMed 

    Google Scholar 

  • 41

    Humphreys-Beher MG and Peck AB (1999) New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model. Arch Oral Biol 44 (Suppl 1): S21–S25

    Article 

    Google Scholar 

  • 42

    Gordon TP et al. (2001) Autoantibodies in primary Sjögren’s syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 34: 123–132

    CAS 
    Article 

    Google Scholar 

  • 43

    Dawson LJ et al. (2006) Antimuscarinic antibodies in primary Sjögren’s syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum 54: 1165–1173

    CAS 
    Article 

    Google Scholar 

  • 44

    Kovacs L et al. (2005) Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3 (213–228) in primary Sjögren’s syndrome. Rheumatology (Oxford) 44: 1021–1025

    CAS 
    Article 

    Google Scholar 

  • 45

    Naito Y et al. (2005) Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren’s syndrome. Ann Rheum Dis 64: 510–511

    CAS 
    Article 

    Google Scholar 

  • 46

    Naito Y et al. (2006) Altered peptide ligands regulate muscarinic acetylcholine receptor reactive T cells of patients with Sjögren’s syndrome. Ann Rheum Dis 65: 269–271

    CAS 
    Article 

    Google Scholar 

  • 47

    Rhodus NL and Schuh MJ (1991) Effects of pilocarpine on salivary flow in patients with Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol 72: 545–549

    CAS 
    Article 

    Google Scholar 

  • 48

    Vivino FB et al. (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 159: 174–181

    CAS 
    Article 

    Google Scholar 

  • 49

    Van de Merwe JP and Arendsen HJ (2000) Interstitial cystitis: a review of immunological aspects of the aetiology and pathogenesis, with a hypothesis. BJU Int 85: 995–999

    CAS 
    Article 

    Google Scholar 

  • 50

    Haarala M et al. (2000) Lower urinary tract symptoms in patients with Sjögren’s syndrome and systemic lupus erythematosus. Int Urogynecol J Pelvic Floor Dysfunct 11: 84–86

    CAS 
    Article 

    Google Scholar 

  • 51

    Leppilahti M et al. (2003) Interstitial cystitis-like urinary symptoms among patients with Sjögren’s syndrome: a population-based study in Finland. Am J Med 115: 62–65

    Article 

    Google Scholar 

  • 52

    Dafni UG et al. (1997) Prevalence of Sjögren’s syndrome in a closed rural community. Ann Rheum Dis 56: 521–525

    CAS 
    Article 

    Google Scholar 

  • 53

    Thomas E et al. (1998) Sjögren’s syndrome: a community-based study of prevalence and impact. Br J Rheumatol 37: 1069–1076

    CAS 
    Article 

    Google Scholar 

  • 54

    Van de Merwe JP et al. (1994) Sjögren’s syndrome, keratoconjunctivitis sicca and focal lymphocytic sialoadenitis in patients with interstitial cystitis. In Sjögren’s Syndrome—State of the Art Proceedings of the Fourth International Symposium, 347–349 (Eds Homma M et al.) Amsterdam: Kugler Publications

    Google Scholar 

  • 55

    Vitali C et al. (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554–558

    CAS 
    Article 

    Google Scholar 

  • 56

    Tyagi S et al. (2006) Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 176: 1673–1678

    CAS 
    Article 

    Google Scholar 

  • 57

    Harriss DR et al. (1995) Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 154: 1241–1245

    CAS 
    Article 

    Google Scholar 

  • 58

    Mukerji G et al. (2006) Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 176: 367–373

    CAS 
    Article 

    Google Scholar 

  • 59

    Mansfield KJ et al. (2005) Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144: 1089–1099

    CAS 
    Article 

    Google Scholar 

  • 60

    Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147 (Suppl 2): S80–S87

    CAS 
    Article 

    Google Scholar 

  • 61

    Wang F et al. (2004) Passive transfer of Sjögren’s syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum 50: 3637–3645

    CAS 
    Article 

    Google Scholar 

  • 62

    Siden A and Lindahl G (1990) Signs of Sjögren’s syndrome in a patient with myasthenia gravis. Acta Neurol Scand 81: 179–180

    CAS 
    Article 

    Google Scholar 

  • 63

    Hughes BW et al. (2004) Pathophysiology of myasthenia gravis. Semin Neurol 24: 21–30

    Article 

    Google Scholar 

  • 64

    Kohn LD and Harii N (2003) Thyrotropin receptor autoantibodies (TSHRAbs): epitopes, origins and clinical significance. Autoimmunity 36: 331–337

    CAS 
    Article 

    Google Scholar 

  • 65

    Bouchelouche K et al. (2006) Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1β and tumor necrosis factor-α. Urology 67: 214–219

    Article 

    Google Scholar 

  • 66

    Chen MC et al. (2007) RANTES mediates TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. Am J Physiol Renal Physiol 292: F1372–F1379

    CAS 
    Article 

    Google Scholar 

  • 67

    Sant GR et al. (2007) The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 69 (4 Suppl): 34–40

    Article 

    Google Scholar 

  • 68

    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725

    CAS 
    Article 

    Google Scholar 

  • Is IC an Autoimmune Condition?

    Behind the redness, swelling, heat and pain of any infection or injury, a biological war is occurring. Injured cells release chemicals that alert our immune system that something is wrong. One of these chemicals, chemokines, attract and direct white blood cells (i.e. macrophages, lymphocytes) to the injured area where they swarm and kill invading bacteria or microbes, ingest debris, eliminate foreign matter and trigger the repair of tissue. This acute inflammation response also causes an increase in blood flow (vasodilation), swelling, pain and heat that usually lasts only a few hours or days.

    Inflammation is essential to healing. Without it, even the smallest of infections could become life threat- ening but when uncontrolled, inflammation plays a role in almost every major disease, including cancer, heart disease, diabetes, Alzheimers and depression. A poor diet, smoking, alcoholism and obesity are well known to promote chronic inflammation.

    In 2016, several studies sought to determine what role, if any, inflammation plays in IC, especially Hunner’s lesions. They produced yet more compelling evidence that Hunner’s lesions are a separate, distinct disorder of the bladder.

    Urine levels of Macrophage Migration Inhabitory Factor Are Increase In Patients With Inflammation

    In an interesting international study, researchers sought to determine if macrophage inhibitory factor, a pro-inflammatory cytokine, increased in patients with inflammatory diseases of the bladder. They studied IC patients with and without Hunner’s lesions, as well as patients with UTI and radiation cystitis.Their results found that patients with

    Hunner’s lesions had higher levels of MIF when compared to IC patients without, suggesting that MIF could serve as a marker to distinguish between the two conditions. It’s worth noting that a study in 2014 (Polyomavirus BK–a potential new therapeutic target for painful bladder syndrome/interstitial cystitis?) found that patients with Hunner’s lesions had a virus in their urine which could explain the increased inflam- matory response. Not surprisingly, patients with UTI and radiation cystitis also had higher levels which makes sense given the fact that the body is defending itself against infection and radiation damage.

    Source: Ma, F, et al. Urine levels of macrophage migration inhibitory factorare increased in patients with bladder inflammation. AUA 2016 Abstract MP72-01

    B-Cell Lymphocytes Found In Higher Quantities in Hunner’s Lesions Patients

    A second study also sought to determine the type of immune response that occurs in Hunner’s lesions. Researchers in Japan took biopsies from 27 lesion patients, 39 non lesion IC patients and 15 non- IC patients and studied the infiltration, if any, of T-lymphocytes, B-lymphocytes, (lymphocytes created by bone marrow), plasma cells and the depth of the bladder epithelium. Their study demonstrated that B-cell lymphocytes were found in significantly higher levels in patients with lesions. They also found that the epithelium was significantly smaller when compared to other patients. They conclude that Hunner’s lesions are, indeed, a distinct inflammatory disorder.

    Source: Akiyama Y, et al. Frequent expansion of clonal B-cells suggestive of specific immune responses in Hunner type IC. AUA 2016 Abstr act MP72-02

    Urinary Chemokines May Predict IC/BPS in Patients With Urinary Symptoms

    Researchers in Japan compared both immune and inflammatory urine markers in IC patients with Hunner’s lesions, IC patients without lesions, overactive bladder patients and controls. They found that IC/BPS patients had increased levels of vascular endothelial growth factor, fibroblast growth factor and several T-helper related chemokines. They did not find, however, a distinct difference between the two groups of IC patients. However, they did find that urinary symptoms did correlate with specific markers, particularly CSCL10.

    Source: Furata A, et al. Urinary chemokines as predictors of IC/BPS in patients with lower urinary tract symptoms. AUA 2016 Abstract MP72- 03

    Urinary Chemokines Predict Functional Bladder Capacity

    Researchers in Michigan and Taiwan collaborated to determine if inflammatory chemokine/cytokine levels correlated with functional bladder capacity. They took urinary specimens from non ulcerative IC patients who had decreased bladder capacity vs. normal bladder capacity. Thirteen specific cytokines were measured demonstrating that there was a strong and significant correlation between inflammation and functional bladder capacity. They suggest that these measurements could be used in the phenotyping of IC patients as well.

    Source: Lamb L, et al. Dexpression of multiplex urine cytokines discriminate functional bladder capacity in IC patients. AUA 2016 Abstract MP72-07

    (PDF) Interstitial cystitis and systemic autoimmune diseases

    r e v i e w

    490 nAtUre clinicAl prActice UROLOGY vAn De meRWe septembeR 2007 vOL 4 nO 9

    www.nature.com/clinic alpractice/uro

    KEY POINTS

    ■ The association within patients and families

    between interstitial cystitis (IC) and known

    autoimmune diseases and a female

    preponderance suggest an autoimmune nature

    of IC, although direct evidence clearly showing

    autoimmune mechanisms is lacking

    ■ The strongest association is between IC

    and Sjögren’s syndrome, a disease in

    which autoantibodies to the muscarinic M3

    receptor on exocrine cells are important in the

    pathogenesis

    ■ Muscarinic M3 receptors are also expressed

    on detrusor smooth muscle cells, where they

    mediate cholinergic contraction of the urinary

    bladder

    ■ Autoantibodies that target muscarinic M3

    receptors might therefore have a role in the

    pathogenesis of IC

    References

    1 Nordling J et al. (2004) Primary evaluation of patients

    suspected of having interstitial cystitis (IC). Eur Urol 45:

    662–669

    2 Erickson DR et al. (2001) Nonbladder related

    symptoms in patients with interstitial cystitis. J Urol

    166: 557–561

    3 Ito T et al. (2000) Interstitial cystitis in Japan. BJU Int

    86: 634–637

    4 Curhan GC et al. (1999) Epidemiology of interstitial

    cystitis: a population based study. J Urol 161: 549–552

    5 Rosenberg MT and Hazzard M (2005) Prevalence of

    interstitial cystitis symptoms in women: a population

    based study in the primary care office. J Urol 174:

    2231–2234

    6 Leppilahti M et al. (2005) Prevalence of clinically

    confirmed interstitial cystitis in women: a population

    based study in Finland. J Urol 174: 581–583

    7 Temml C et al. (2006) Prevalence and correlates for

    interstitial cystitis symptoms in women participating in

    a health screening project. Eur Urol 51: 803–808

    8 Propert KJ et al. (2000) A prospective study of interstitial

    cystitis: results of longitudinal followup of the interstitial

    cystitis data base cohort. The Interstitial Cystitis Data

    Base Study Group. J Urol 163: 1434–1439

    9 Jones CA et al. (1994) Prevalence of interstitial cystitis

    in the United States. J Urol 151: 423A

    10 Abrams P et al. (2002) The standardisation of

    terminology of lower urinary tract function: report from

    the Standardisation Sub-committee of the International

    Continence Society. Neurourol Urodyn 21: 167–178

    11 Oberpenning F et al. (2002) Interstitial cystitis: an

    update. Curr Opin Urol 12: 321–332

    12 Van de Merwe JP et al. (1993) Sjögren’s syndrome

    in patients with interstitial cystitis. J Rheumatol 20:

    962–966

    13 Van de Merwe JP (2003) Sjögren’s syndrome in

    patients with interstitial cystitis. Preliminary results

    in 100 patients. Int J Urol 10 (Suppl): S69

    14 Alagiri M et al. (1997) Interstitial cystitis: unexplained

    associations with other chronic disease and pain

    syndromes. Urology 49 (5A Suppl): S52–S57

    15 Yamada T (2003) Significance of complications of

    allergic diseases in young patients with interstitial

    cystitis. Int J Urol (10 Suppl): S56–S58

    16 Peeker R

    et al. (2003) Intercurrent autoimmune

    conditions in classic and non-ulcer interstitial cystitis.

    Scand J Urol Nephrol 37: 60–63

    17 Ochs RL and Tan EM (1997) Autoimmunity and

    interstitial cystitis. In Interstitial Cystitis, 47–52

    (Ed. Sant GR) Philadelphia: Lippincott-Raven

    18 Ochs RL et al. (1994) Autoantibodies in interstitial

    cystitis. J Urol 151: 587–592

    19 Keay S et al. (1997) Urine autoantibodies in interstitial

    cystitis. J Urol 157: 1083–1087

    20 Danchenko N et al. (2006) Epidemiology of systemic

    lupus erythematosus: a comparison of worldwide

    disease burden. Lupus 15: 308–318

    21 Alarçon-Segovia D et al. (1984) Involvement of the

    urinary bladder in systemic lupus erythematosus.

    A pathologic study. J Rheumatol 11: 208–210

    22 Grennan DM et al. (1977) Sjögren’s syndrome in SLE:

    Part 2. An examination of the clinical significance of

    Sjögren’s syndrome by comparison of its frequency in

    typical and atypical forms of SLE, overlap syndromes

    and scleroderma. N Z Med J 86: 376–379

    23 Andonopoulos AP et al. (1990) Sjögren’s syndrome

    in systemic lupus erythematosus. J Rheumatol 17:

    201–204

    24 Gilboe IM et al. (2001) Sicca symptoms and

    secondary Sjögren’s syndrome in systemic lupus

    erythematosus: comparison with rheumatoid arthritis

    and correlation with disease variables. Ann Rheum

    Dis 60: 1103–1109

    25 Drosos AA et al. (1990) Subacute cutaneous lupus

    erythematosus in Greece. A clinical, serological and

    genetic study. Ann Med Interne (Paris) 141: 421–424

    26 Chen MY et al. (2004) Is there an ethnic difference in

    the prevalence of lupus cystitis? A report of six cases.

    Lupus 13: 263–269

    27 Vercammen M et al. (2007) Diagnostic accuracy

    of the FIDIS multiplex fluorescent microsphere

    immunodetection system for anti-extractable

    nuclear antigen (ENA) antibodies in connective tissue

    diseases. Clin Chem Lab Med 45: 505–512

    28 Sauerland U et al. (2005) Clinical utility of the anti-CCP

    assay: experiences with 700 patients. Ann NY Acad

    Sci 1050: 314–318

    29 Van Noord C et al. (2005) Diagnostic value of anti-

    cyclic citrullinated peptide antibodies to detect

    rheumatoid arthritis in patients with Sjögren’s

    syndrome. Ann Rheum Dis 64: 160–162

    30 Cohen MG and Webb J (1987) Concurrence of

    rheumatoid arthritis and systemic lupus erythematosus:

    report of 11 cases. Ann Rheum Dis 46: 853–858

    31 Alarçon-Segovia D et al. (2005) Familial aggregation of

    systemic lupus erythematosus, rheumatoid arthritis, and

    other autoimmune diseases in 1,177 lupus patients from

    the GLADEL cohort. Arthritis Rheum 52: 1138–1147

    32 Andonopoulos AP et al. (1987) Secondary Sjogren’s

    syndrome in rheumatoid arthritis. J Rheumatol 14:

    1098–1103

    33 Lee KL et al. (2006) Lower urinary tract symptoms in

    female patients with rheumatoid arthritis. Scand J

    Rheumatol 35: 96–101

    34 Fox RI et al. (1984) Primary Sjögren syndrome: clinical

    and immunopathologic features. Semin Arthritis

    Rheum 14: 77–105

    35 Asherson RA et al. (1992) Antiphospholipid antibodies

    and HLA associations in primary Sjögren’s syndrome.

    Ann Rheum Dis 51: 495–498

    36 Yasuda S et al. (2004) Abacterial prostatitis and

    primary biliary cirrhosis with Sjögren’s syndrome. Mod

    Rheumatol 14: 70–72

    37 Ramos-Casals M et al. (2006) Atypical autoantibodies

    in patients with primary Sjögren syndrome: clinical

    characteristics and follow-up of 82 cases. Semin

    Arthritis Rheum 35: 312–321

    © 2007 Nature Publishing Group

    Establishment of a Novel Autoimmune Experimental Model of Bladder Pain Syndrome/Interstitial Cystitis in C57BL/6 Mice

  • 1.

    Altman, D., C. Lundholm, I. Milsom, R. Peeker, M. Fall, A.N. Iliadou, and N.L. Pedersen. 2011. The genetic and environmental contribution to the occurrence of bladder pain syndrome: an empirical approach in a nationwide population sample. European Urology 59(2): 280–285. doi:10.1016/j.eururo.2010.10.028.

    Article 
    PubMed 

    Google Scholar 

  • 2.

    Altuntas, C.Z., F. Daneshgari, C. Sakalar, E. Goksoy, M.F. Gulen, M. Kavran, J. Qin, X. Li, and V.K. Tuohy. 2012. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. European Urology 61(1): 193–200. doi:10.1016/j.eururo.2011.06.028.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 3.

    Bogart, L.M., S.H. Berry, and J.Q. Clemens. 2007. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. Journal of Urology 177(2): 450–456. doi:10.1016/j.juro.2006.09.032.

    Article 
    PubMed 

    Google Scholar 

  • 4.

    Bullock, A.D., M.J. Becich, C.G. Klutke, and T.L. Ratliff. 1992. Experimental autoimmune cystitis: a potential murine model for ulcerative interstitial cystitis. Journal of Urology 148(6): 1951–1956.

    CAS 
    PubMed 

    Google Scholar 

  • 5.

    Chen, M.C., P. Keshavan, G.D. Gregory, and D.J. Klumpp. 2007. RANTES mediates TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. American Journal of Physiology. Renal Physiology 292(5): F1372–1379. doi:10.1152/ajprenal.00472.2006.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 6.

    Chou, L.W., J. Wang, P.L. Chang, and Y.L. Hsieh. 2011. Hyaluronan modulates accumulation of hypoxia-inducible factor-1 alpha, inducible nitric oxide synthase, and matrix metalloproteinase-3 in the synovium of rat adjuvant-induced arthritis model. Arthritis Research and Therapy 13(3): R90. doi:10.1186/ar3365.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • 7.

    Clemens, J.Q., R.T. Meenan, M.C. Rosetti, S.Y. Gao, and E.A. Calhoun. 2005. Prevalence and incidence of interstitial cystitis in a managed care population. Journal of Urology 173(1): 98–102. doi:10.1097/01.ju.0000146114.53828.82. discussion 102.

    Article 
    PubMed 

    Google Scholar 

  • 8.

    Cornelissen, L.L., B. Misajet, D.P. Brooks, and A. Hicks. 2008. Influence of genetic background and gender on bladder function in the mouse. Autonomic Neuroscience 140(1-2): 53–58. doi:10.1016/j.autneu.2008.04.001.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 9.

    DeBerry, J.J., E.S. Schwartz, and B.M. Davis. 2014. TRPA1 mediates bladder hyperalgesia in a mouse model of cystitis. Pain 155(7): 1280–1287. doi:10.1016/j.pain.2014.03.023.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • 10.

    Gonzalez, R.R., T. Fong, N. Belmar, M. Saban, D. Felsen, and A. Te. 2005. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. Journal of Urology 173(2): 630–634. doi:10.1097/01.ju.0000143192.68223.f7.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 11.

    Hauser, P.J., D.A. Buethe, J. Califano, T.M. Sofinowski, D.J. Culkin, and R.E. Hurst. 2009. Restoration of the barrier function to acid-damaged bladder by intravesical chondroitin sulfate. Journal of Urology 182(5): 2477–2482. doi:10.1016/j.juro.2009.07.013.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • 12.

    Homan, Takashi, Tetsunori Tsuzuki, Koji Dogishi, Hisashi Shirakawa, Tatsuya Oyama, Takayuki Nakagawa, and Shuji Kaneko. 2013. A novel mouse model of chronic inflammatory and overactive bladder by a single intravesical injection of hydrogen peroxide. Journal of Pharmacological Sciences 121(4): 327–337. doi:10.1254/jphs.12265FP.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 13.

    Izgi, K., C.Z. Altuntas, F. Bicer, A. Ozer, C. Sakalar, X. Li, V.K. Tuohy, and F. Daneshgari. 2013. Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PloS One 8(8): e72067. doi:10.1371/journal.pone.0072067.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • 14.

    Lin, Y.H., G. Liu, M. Kavran, C.Z. Altuntas, G. Gasbarro, V.K. Tuohy, and F. Daneshgari. 2008. Lower urinary tract phenotype of experimental autoimmune cystitis in mouse: a potential animal model for interstitial cystitis. BJU International 102(11): 1724–1730. doi:10.1111/j.1464-410X.2008.07891.x.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 15

    Logadottir, Y., D. Delbro, C. Lindholm, M. Fall, and R. Peeker. 2014. Inflammation characteristics in bladder pain syndrome ESSIC type 3C/classic interstitial cystitis. International Journal of Urology 21(Suppl 1): 75–78. doi:10.1111/iju.12370.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 16

    Lorenzo Gomez, M.F., and S. Gomez Castro. 2004. Physiopathologic relationship between interstitial cystitis and rheumatic, autoimmune, and chronic inflammatory diseases. Archivos Españoles de Urología 57(1): 25–34.

    PubMed 

    Google Scholar 

  • 17

    Moutzouris, D.A., and M.E. Falagas. 2009. Interstitial cystitis: an unsolved enigma. Clinical Journal of the American Society of Nephrology 4(11): 1844–1857. doi:10.2215/CJN.02000309.

    Article 
    PubMed 

    Google Scholar 

  • 18

    Nickel, J.C., D.A. Tripp, M. Pontari, R. Moldwin, R. Mayer, L.K. Carr, R. Doggweiler, C.C. Yang, N. Mishra, and J. Nordling. 2010. Psychosocial phenotyping in women with interstitial cystitis/painful bladder syndrome: a case control study. Journal of Urology 183(1): 167–172. doi:10.1016/j.juro.2009.08.133.

    Article 
    PubMed 

    Google Scholar 

  • 19

    Olivar, T., and J.M. Laird. 1999. Cyclophosphamide cystitis in mice: behavioural characterisation and correlation with bladder inflammation. European Journal of Pain 3(2): 141–149. doi:10.1053/eujp.1998.0105.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 20

    Peeker, R., L. Atanasiu, and Y. Logadottir. 2003. Intercurrent autoimmune conditions in classic and non-ulcer interstitial cystitis. Scandinavian Journal of Urology and Nephrology 37(1): 60–63. doi:10.1080/00365590310008721.

    Article 
    PubMed 

    Google Scholar 

  • 21

    Pennefather, J.N., A. Lecci, M.L. Candenas, E. Patak, F.M. Pinto, and C.A. Maggi. 2004. Tachykinins and tachykinin receptors: a growing family. Life Sciences 74(12): 1445–1463.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 22

    Pinto, L.G., T.M. Cunha, S.M. Vieira, H.P. Lemos, W.A. Verri Jr., F.Q. Cunha, and S.H. Ferreira. 2010. IL-17 mediates articular hypernociception in antigen-induced arthritis in mice. Pain 148(2): 247–256. doi:10.1016/j.pain.2009.11.006.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 23

    Saban, Ricardo, Marcia R. Saban, Ngoc-Bich Nguyen, Bao Lu, Craig Gerard, Norma P. Gerard, and Timothy G. Hammond. 2000. Neurokinin-1 (NK-1) receptor is required in antigen-induced cystitis. American Journal of Pathology 156(3): 775–780. doi:10.1016/s0002-9440(10)64944-9.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • 24

    Shao, Y., G.L. Lu, Z.J. Shen, and H.C. He. 2013. Reduction of intercellular adhesion molecule 1 may play a role in anti-inflammatory effect of hyaluronic acid in a rat model of severe non-bacterial cystitis. World Journal of Urology 31(3): 535–540. doi:10.1007/s00345-012-0839-8.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 25

    van de Merwe, J.P. 2007. Interstitial cystitis and systemic autoimmune diseases. Nature Clinical Practice Urology 4(9): 484–491. doi:10.1038/ncpuro0874.

    Article 
    PubMed 

    Google Scholar 

  • 26

    Wang, Z.Y., P. Wang, and D.E. Bjorling. 2014. Treatment with a cannabinoid receptor 2 agonist decreases severity of established cystitis. Journal of Urology 191(4): 1153–1158. doi:10.1016/j.juro.2013.10.102.

    CAS 
    Article 
    PubMed 

    Google Scholar 

  • 27

    Yu, W., C. Ackert-Bicknell, J.D. Larigakis, B. MacIver, W.D. Steers, G.A. Churchill, W.G. Hill, and M.L. Zeidel. 2014. Spontaneous voiding by mice reveals strain-specific lower urinary tract function to be a quantitative genetic trait. American Journal of Physiology. Renal Physiology 306(11): F1296–1307. doi:10.1152/ajprenal.00074.2014.

    CAS 
    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Interstitial Cystitis (Painful Bladder Syndrome): Causes & Treatment



    Overview

    What is interstitial cystitis (IC)?

    Interstitial cystitis (IC) or painful bladder (PBS) is defined as a pain, pressure, or discomfort in the suprapubic or bladder area which can cause urinary frequency or the urge to urinate that has been present for at least six weeks.

    Who gets interstitial cystitis (IC)?

    Men, women and children can all be diagnosed with IC. It is estimated that approximately 83,000 men and 1.2 million women in the US suffer from IC.



    Symptoms and Causes

    What causes interstitial cystitis (IC)?

    The causes for IC are not completely understood. IC may be related to such medical conditions as:

    • Autoimmune disease.
    • Allergies.
    • Defects in the lining of the bladder.
    • Vascular (blood vessel) disease.
    • Mast cell (cells that cause allergic symptoms) abnormalities.
    • Presence of abnormal substances in the urine.
    • Unidentified infections.

    What are the symptoms of interstitial cystitis (IC)?

    Symptoms of IC/PBS vary from case to case, and can be mild, severe, occasional or constant. The symptoms may be similar to those of a bladder infection. Women’s symptoms often get worse during menstrual periods.

    Symptoms of interstitial cystitis (IC) include the following:

    • Suprapubic or pelvic pain.
    • Pressure or discomfort when the bladder is filling.
    • Having to urinate frequently.
    • Urinating small amounts.



    Diagnosis and Tests

    How is interstitial cystitis (IC) diagnosed?

    There are no definitive tests to diagnose IC/PBS. It is important to rule out other infections and conditions so your doctor may run different tests, including:

    • Urine sample and urinalysis: The patient provides a urine sample, and the doctor examines it with a microscope to learn if there are any organisms, germs, pus, or white blood cells, which could mean that there is an infection. The doctor can treat the infection with antibiotics. If the urine is sterile for weeks or months and the symptoms continue, doctors may make a diagnosis of IC.
    • Biopsy of the bladder wall and urethra: A biopsy is a sample of tissue taken from the body in order to examine it more closely. This procedure will be done under anesthesia. Tissue may be taken from the bladder wall and urethra (the tube through which urine passes out of the body) to rule out other conditions. A biopsy can help rule out bladder cancer.
    • Cystoscopy: The doctor may examine the inside of the bladder with an instrument called a cystoscope. This is a long, thin scope with an eyepiece on one end. The cystoscope is gently placed up the urethra and into the bladder. The doctor can see into the bladder by looking through the eyepiece. The patient is not under anesthesia during this procedure. A cystoscopy can rule out bladder cancer. If a bladder biopsy is also planned, the cystoscopy may be performed at the same time, but this may require anesthesia.
    • Cystoscopy under anesthesia with bladder distension: A cystoscopy may also be done with bladder distention (stretching). The doctor will perform a cystoscopy as described above and will distend (stretch) the bladder to its maximum capacity by filling it with water. This procedure can reveal cracks in the bladder. This procedure requires anesthesia because the stretching is painful for people with IC. After this procedure, many IC/PBS patients experience temporary relief of their symptoms.



    Management and Treatment

    How is interstitial cystitis (IC) treated?

    Although IC/PBS cannot be cured, there are many ways to treat it. There is no way to predict who will respond best to certain treatments. Symptoms of IC/PBS may become more severe, or may disappear. Even if symptoms disappear, they may return after days, weeks, months or years.

    Treatments for IC/PBS are aimed at relieving symptoms. Doctors will help decide the appropriate treatment for the patient. For some patients, treatments are combined.

    Interstitial cystitis/painful bladder treatments can include:

    • Diet: Some people with IC/PBS find that certain foods or drinks make their symptoms worse. You may find it helpful to keep a diary of what you eat and drink to see if any foods or drinks cause symptoms and/or flare-ups. For patients who have IC/PBS, acidic foods may irritate the bladder. If this is the case, your doctor may recommend taking an antacid with meals to reduce the amount of acid that gets into the urine. You may also want to remove certain foods from your diet, such as:
      • Alcohol
      • Caffeine
      • Carbonated beverages
      • Chocolate
      • Tomatoes
      • Artificial sweeteners
    • Physical activity: Exercise and physical activity may help relieve the symptoms of IC/PBS. Exercises can include:
      • Walking
      • Biking
      • Gentle stretching
    • Reducing stress: Stress can trigger flare-ups and symptoms in someone who has IC/PBS. Learning stress reduction methods and setting aside time for relaxation may make living with IC/PBS easier.
    • Physical therapy: The pelvic muscles hold the bladder in place and help control urination. Exercising these muscles may help reduce the symptoms of IC/PBS. Your doctor or physical therapist can help you perform this exercises correctly.
    • Bladder retraining: A person who has bladder pain can get in the habit of using the bathroom as soon as he or she feels pain or urgency, even if the bladder is not full. As a result, his or her body may get used to going to the bathroom often. Bladder retraining is a treatment to try to overcome this habit by helping you hold urine for a longer period of time. To use bladder retraining, keep a diary of how often you urinate, and how often you have the urge to urinate. Use the diary to gradually increase the length of time between bathroom breaks.
    • Oral medications: Pentosan polysulfate sodium (Elmiron®) is a medication approved for treating the pain of IC. This medication may have to be taken for up to six months before any improvement is noticed. Medicines that treat heartburn may help the symptoms of IC by reducing the amount of acid made by the body. Muscle relaxants can help relieve the symptoms by keeping the bladder from squeezing at the wrong time. Antidepressants can be used to relieve pain in patients with IC. Tricyclic antidepressants such as amitriptyline (Elavil) have been shown to improve pain and reduce frequent urination in patients with IC. Narcotic pain medications are not routinely used to treat pain in IC patients.
    • Bladder instillations: Another treatment is to fill the bladder with a liquid medicine. You place a small catheter or tube in the urethra and fill the bladder with medicine.
    • Bladder stretching/hydrodistension: Bladder stretching or hydrodistension is a procedure that is performed in the operating room under anesthesia. The bladder is filled with sterile water in order to distend the bladder and increase the amount of urine you can hold.
    • Nerve stimulation: Nerve stimulation is a treatment that helps regulate the bladder. These treatments are more helpful in reducing urgency and urinary frequency but sometimes can help with the bladder/suprapubic pain.
    • Surgery: Surgery to treat IC/PBS is used as a last resort. The surgery may remove parts of the bladder or even the entire bladder. If the patient has tried every other treatment option and pain is unbearable, surgery may be considered.

    Interstitial Cystitis | Johns Hopkins Medicine

    What is interstitial cystitis?

    Interstitial cystitis (IC) is an inflamed or irritated bladder wall. It can lead to scarring and stiffening of the bladder. The bladder can’t hold as much urine as it did in the past. It is a chronic disorder. IC may also be known as:

    What causes interstitial cystitis?

    The cause of interstitial cystitis (IC) is unknown. Researchers are looking at many theories to understand the causes of IC and find the best treatments.

    Most people with IC find that certain foods make their symptoms worse. These include:

    What are the symptoms of interstitial cystitis?

    These are the most common symptoms of interstitial cystitis (IC):

    • Frequent urination

    • Urgency with urination

    • Feelings of pressure, pain, and tenderness around the bladder, pelvis, and the area between the anus and vagina or anus and scrotum (perineum)

    • Pain during sex

    • In men, discomfort or pain in the penis and scrotum

    • In women, symptoms may worsen around their period

    Stress may also make symptoms worse, but stress does not cause symptoms.

    The symptoms of IC may look like other conditions or medical problems. Always talk with a healthcare provider for a diagnosis.

    How is interstitial cystitis diagnosed?

    No single test can diagnose IC. And symptoms of IC are a lot like those of other urinary disorders. For these reasons, a variety of tests may be needed to rule out other problems. Your healthcare provider will start by reviewing your medical history and doing a physical exam. Other tests may include:

    • Urinalysis. Lab testing of urine to look for certain cells and chemicals. This includes red and white blood cells, germs, or too much protein.

    • Urine culture and cytology. Collecting and checking urine for white blood cells and bacteria. Also, if present, what kind of bacteria there are in the urine.

    • Cystoscopy. A thin, flexible tube and viewing device, is put in through the urethra to examine the bladder and other parts of the urinary tract. This checks for structural changes or blockages.

    • Bladder wall biopsy. A test in which tissue samples are removed from the bladder (with a needle or during surgery) and checked under a microscope to see if cancer or other abnormal cells are present.

    • Lab exam of prostate secretions (in men). This is done to look for inflammation and/or infection of the prostate.

    How is interstitial cystitis treated?

    There is no cure for IC and it can be hard to treat. Treatments are aimed at easing symptoms, and may include:

    • Bladder enlargement. This method increasing bladder capacity. It also interferes with pain signals being sent by the nerve cells in the bladder.

    • Bladder wash. The bladder is filled with a solution that is held for varying times, from a few seconds to 15 minutes. Then it is drained out through a catheter.

    • Medicine. Medicine may be taken by mouth or put right into the bladder. There are many different drugs that may be used.

    • Transcutaneous electrical nerve stimulation (TENS). Mild, electric pulses enter the body for minutes to hours, 2 or more times a day. The pulses are sent through wires placed on the lower back, or through special devices put into the vagina in women or into the rectum in men. For some people, TENS eases bladder pain and urinary frequency and urgency.

    • Bladder training. You urinate at specific times and use relaxation techniques and distractions to help keep to the schedule. Over time, you try to lengthen the time between the scheduled voids.

    • Surgery. Surgery to remove all or part of the bladder may be done in severe cases, if other treatments do not work.

    Management of IC may also include:

    • Diet changes. No proof links diet to IC, but some believe that alcohol, tomatoes, spices, chocolate, caffeinated and citrus beverages, and high-acid foods may contribute to bladder inflammation. Removing these from the diet may help to decrease some symptoms.

    • Not smoking. Many people with IC find that smoking makes their symptoms worse.

    • Exercise. Exercise may help ease symptoms or make them stop for a while.

    • Reducing stress. There is no proof that stress causes IC. But, if a person has IC, stress can make the symptoms worse.

    Talk with a healthcare provider with any questions of concerns you may have about this health problem.

    Key points about interstitial cystitis

    • Interstitial cystitis (IC) is an inflamed or irritated bladder wall.

    • The cause of IC is unknown and it does not get better with antibiotics.

    • Symptoms of IC include changes in urination such as frequency and urgency; pressure, pain, and tenderness around the bladder, pelvis, and the area between the anus and vagina or anus and scrotum; and pain during sex.

    • There is no best way to diagnose IC. A variety of tests may be needed. Urine tests will be done and imaging tests may be used to look at the different parts of the urinary tract and make sure everything is normal. Tissue samples may be removed from the bladder (with a needle or during surgery) and examined under a microscope to see if cancer or other abnormal cells are present.

    • Treatments are aimed at easing symptoms. A variety of procedures, medicines, and lifestyle changes may be advised.

    90,000 Markers of autoimmune diseases – Paracelsus Medical Center

    Service selected:

    Choosing a specialist service

    Click to select a service

    Select date and address

    Back

    A repeated consultation is considered to be a consultation of one specialist within 30 days from the date of the previous appointment.On the 31st day from the previous visit to a specialist of this profile, the consultation will be primary.

    Hematological manifestations of autoimmune gastritis | Moosie

    1. Chanarin I. A history of pernicious anemia.Br J Haemat 2000; 111: 407-41.

    2. Faber K., Bloch C.E. Ueber die pathologischen Veranderungen am Digestionstractus bei der perniciosier Anamie und uber die sogenannte Darmatrophie. Ztschr f klin Med 1900; 40:98.

    3. Taylor K.B., Morton J.A. An antibody to Castle’s intrinsic factor. J Path Bact 1959; 77: 117.

    4.Irvine W.J., Davies S.H., Teitelbaum S., Delamore I.W., Williams A.W. The clinical and pathological significance of gastric parietal cell antibody. Ann N Y Acad Sci 1965; 124: 657-91.

    5. Lahner E., Annibale B. Pernicious anemia: New insights from a gastroenterological point of view. World J Gastroenterol 2009; 15: 5121-8.

    6. Irvine W.J. Clinical and pathological significance of parietal cell antibodies. Proc R Soc Med 1966; 59: 695-8.

    7. Andres E., Serraj K. Optimal management of pernicious anemia. J Blood Med 2012; 3: 97-103.

    8. Ye W., Nyrén O. Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalized for pernicious anemia.Gut 2003; 52: 938-41.

    9. Lechner K., Födinger M., Grisold W., Püspök A., Sillaber C. Vitamin B12 deficiency. New data on an old theme. Wien Klin Wochenschr 2005; 117: 579-91.

    10. Oh R.C., Brown D.L. Vitamin B12 deficiency. Am Fam Physician 2003; 67: 993-4.

    11.Gisbert J.P., Gomollón F. A short review of malabsorption and anemia. World J Gastroenterol 2009; 15: 464452.

    12. Okorokov A. N. Diagnostics of diseases of internal organs. Diagnosis of diseases of the blood system. M .: Med. Litter; 2001.

    13. Froese D.S., Gravel R.A. Genetic disorders of vitamin B12 metabolism: eight complementation groups – eight genes.Expert Rev Mol Med 2010; 12:37.

    14. Beghé C., Wilson A., Ershler W.B. Prevalence and outcomes of anemia in geriatrics: a systematic review of the literature. Am J Med 2004; 116: 3-10.

    15. Chulilla J.A.M., Colás M.S.R., Martín M.G. Classification of anemia for gastroenterologists. World J Gastroenterol 2009; 15: 4627-37.

    16.Cabot R.C. Pernicious anemia (cryptogenic). A System of Medicine. London, 1908.

    17. Andrès E., Vogel T., Federici L., Zimmer J., Ciobanu E., Kaltenbach G. Cobalamin deficiency in elderly patients: a personal view. Curr Gerontol Geriatr Res 2008: 848267.

    18. Nafil H., Tazi I., Sifessalam M., Bouchtia M., Mahmal L. Clinical, biological and therapeutic profile of anemia by vitamin B12 deficiency in the department of hematology of Marrakech (Morocco).Bull Soc Pathol Exot 2013; 106: 83-8.

    19. Song I. C., Lee H. J., Kim H. J., Bae S.B., Lee K. T., Yang Y. J., et. al. A multicenter retrospective analysis of the clinical features of pernicious anemia in a Korean population. J Korean Med Sci 2013; 28: 200-4.

    20. Carmel R. Pernicious anemia. The expected findings of very low serum cobalamin levels, anemia, and macrocytosis are often lacking.Arch Intern Med 1988; 148: 1712-4.

    21. Xiao S.D., Jiang S.J., Shi Y., Zhang D.Z., Hu Y.B., Liu W.Z., Yuan J.M. Pernicious anemia and type A atrophic gastritis in the Chinese. Chin Med J (Engl) 1990; 103: 192-6.

    22. Alonso N., Granada M.L., Salinas I., Lucas A.M., Reverter J.L., Juncà J., Oriol A., Sanmartí A. Serum pepsinogen I: an early marker of pernicious anemia in patients with type 1 diabetes.J Clin Endocrinol Metab 2005; 90: 5254-8.

    23. Muñoz M., Villar I., García-Erce J.A. An update on iron physiology. World J Gastroenterol 2009; 15: 4617-26.

    24. Wang J., Pantopoulos K. Regulation of cellular iron metabolism. Biochem J 2011; 434: 365-81.

    25.Bermejo F., García-López S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol 2009; 15: 4638-43.

    26. Colacci E., Pasquali A., Severi C. Exocrine gastric secretion and gastritis: pathophysiological and clinical relationships. Clin Ter 2011; 162: 19-25.

    27. Johnson-Wimbley T.D., Graham D.Y. Diagnosis and management of iron deficiency anemia in the 21st century. Ther Adv Gastroenterol 2011; 4: 177-84

    28. Vorobiev S.A. Comparative characteristics of the secretory function of the stomach in patients with chronic gastritis against the background of iron B12-deficiency anemia. VIII International Slavic-Baltic Scientific Forum. St. Petersburg, 2006.

    29.Vorobiev S.A., Soloviev V.A., Tkachev V.A. Morphological features and secretory function of the stomach in patients with chronic atrophic gastritis associated with B12-deficiency and iron deficiency anemia. Gastroenterology of St. Petersburg 2007; 1:23.

    30. Hershko C., Hoffbrand A.V., Keret D., Souroujon M., Maschler I., Monselise Y., Lahad A. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia.Haematologica 2005; 90: 585-95.

    31. Marignani M., Delle Fave G., Mecarocci S., Bordi C., Angeletti S., D’Ambra G., et al. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. Am J Gastroenterol 1999; 94: 766-72.

    32. Hershko C., Patz J., Ronson A.The anemia of achylia gastrica revisited. Blood Cells Mol Dis 2007; 39: 178-83.

    Cofactor of anti-lipid antibodies in syphilis, Lyme borreliosis and autoimmune diseases | Voicechovskaya

    1.

    Alarcon-Segivia D. Clinical manifestations of the antiphos-pholoipid syndrome. J. Rheumatol. 1992, 19.1778-1781

    Asherson R.A., Cervera R. “Primary”, secondary and orther variants of the antiphospholipid syndrome. Lupus, 1994, 3, 293-298.

    Costello PB, Green F.A. Reactivity patterns of human anti- cardiolipin and other antiphospholipid antibodies in syphilitic sera. Infect. Immun. 1986, 51, 771-775.

    Gharavi A.E., Harris E.N., Asherson R.A ,. Hughes GRV. Antiphospholipid antibodies: isotype distribution and phospholipid specificity. Ann. Rheum. Dis. 1987, 46, 1-6.

    Gharavi A.E., Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus, 1998, 7, S211

    Harris E.N., Gharavi A.E., Wasley G.D., Hughes G.R.V. Use of enzyme-linked assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J. Infect. Dis. 1988, 157, 23-31.

    Hunt J., Krilis S. A phospholipid-p2-glywcoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with ifection.Lupus, 1992, 1, 75-81.

    Kandiah D.A., Krilis S.A. Immunology and methods of detection of antiphopspholipid antibodies. In: Asherson RA., Cervera R., Piette J.C., Shoenfeld Y. (eds) The antiphospholipid syndrome. CRC Press, USA, 1996, 29

    Lopez-Soto A., Cervera R., Font J. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatic acid, phosphatydilinositol and phosphatidylserine in systemic lupus erythematosus : prospective analysis of a series of 92 patients.Clin. Experimental. 1997, 15, 143-149.

    Luft S. Metody diagnostyki serologicznej w reumatologii. Widawnictwo naukowe PWN, Warszawa. 1996, 101-102.

    McNeil H.P., Chesterman C.N., Krilis S.A. Immunology and clinical importance of antiphospholipid antibodies. Adv. Immunol. 1991, 49, 193-280.

    McNeil H. P., Chesterman C. N., Krilis SA. Anticardiolipin antibodies and lupus anticoagulant separate antibody subgroups with different phospholipid binding characteristics.Br.J. Haematol. 1989, 73,506.

    Poltz E, Kostner G.M. FEBS Letters. 1979, 102, 183.

    Sieve TM ,. B. Voitsekhovskaya, Z. Sapekberova, et al. Antibodies to various phospholipids in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clinic. Honey. 1999, 5, 32-37.

    Reshetniak TM, B. Wojciechowska, Z. Alekberova, et al. Korelacia wystepowania surowiczych przeciwcial antyfos- folipidowych oraz anticoagulantu tocznia z wybranymi objawami klinicznymi u chorych z toczeniem rumieniowatym ukladowym oraz pierwotnypo i wtmymy zesReumatologia 1999, 37, (2) 145-147

    Loizou S.A., Walport M.A., Davies K.A. The antiphospholipid syndrome and infectious diseases. In Asherson R. A., Cervera R., Piette J. C., Shoenfeld Y. (eds) The antiphospholipid syndrome. CRC Press, USA, 1996, 267-287. *

    Weidmann C.E., Wallanca D.J., Peter J.B., et al. Studies of IgG, IgM, and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol. 1993, 20, 1598-1600. •

    Shelley W.B., Shelley E.D. Syphilis. In: Advanced Dermatologic Diagnoses. WB Saunders: Philadelfia, RA, 1992, 1183-1187.

    Zabek J., Luft S., Woiciechowska B., Biemacka E. et al. Badania nad krzywa reakty wicoscia przeciwciab antifos- folipidowych w ukladowych chorobach tkanki lacznej. Reumatologia, 1995, 33 (2), 112

    Zabek J., Woiciechowska B., Luft S. The study on the significance of the apolipoprotein H as an autoantigen and a cofactor or the specific antiphospholipids antibodies reactions.Reumatologia, 1998, 36, 55, 147.

    Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

    This study is a protocol for inducing and monitoring EAE using MOG35-55 in C57BL / 6 mice, considered a typical neuroimmune experimental animal model of MS. EAE can be induced by changing the strains of mice or the type of protein used for induction in accordance with the purpose of the study.For example, the use of the PLP139-151 peptide in SJL mice can induce a relapsing-remitting course of EAEU disease, which is particularly well suited for evaluating the therapeutic effect on 90,085 relapses 15 . The experimental procedure outlined here can be applied to other protocols EAE 7. In this model, C57BL / 6 mice are inoculated with the MOG35-55 peptide and develop monophasic disease. A 5-point scoring system is used to assess the severity of the EAE. Although several scoring systems ranging from 0-3 points or 0-10 points are used to assess disease severity 7 , 16 , 17 , these results indicate that a 5-point scoring system can statistically determine significant differences in disease scores between groups and other EAE scoring systems do not lead to obvious improvement.

    The severity of EAE is generally assessed by the clinical EAE score taking into account the severity of neurological dysfunction 11 , 13 . To ensure comparability of the experiment for all mice, it is important to keep them under the same conditions, including cell changes, administration of food and water, and especially mouse housing conditions. In addition, cross-immunization should also be carried out in order to avoid cell-specific events caused by the investigator.

    This study provides a method for separating mononuclear cells from the central nervous system, which is suitable for FACS analysis or functional research. To ensure that blood is removed from CNS tissue, mice must be infiltrated prior to tissue dissociation. Purification of mononuclear cells in a density gradient centrifuge is a key step in isolation. To provide a separation effect, the acceleration and deceleration of the centrifuge must be set to 1 and 0, respectively. Using this method, the yield of unicellular cells is generally low from a normal brain, but higher from a diseased brain with EAE.Representative results show that there is an apparent increase in CD3 and CD4 and T lymphocytes, especially IFN-γ producing cells and IL-17 producing cells believed to contribute to the worsening of the disease.

    There are some limitations to this protocol. The EAE model induced with MOG35-55 shows a basically immunological cd4 and T cell response. If role of CELL8 and group B T cells is to be analyzed, alternative protocols should be considered.As an inflammatory disease of the CNS, a severe pathological phenotype is also found in the spinal cord in the EAE model. However, due to the large amount of myelin present, it is difficult to obtain a sufficient number of single cells from the spinal cord for FACS analysis. In this case, it is necessary to use immunohistochemistry or immunofluorescence to analyze the tissues of the spinal cord. There are also researchers who put the brain and spinal cord together to separate mononuclear cells for FACS analysis 12 .This protocol separates single cells from the brain for FACS analysis and spinal cord tissue for immunohistochemistry and immunofluorescence analysis.

    The importance of T-lymphocytes in the immune regulation of MS and EAO has recently received more and more attention. Most of the published literature is devoted to the spleen and lymph nodes 90,085 11; however, lymphocytes are found throughout the CNS of EAE mice and thus a characteristic analysis of T lymphocytes in the CNS is required. Immunohistological staining of sections can identify invading cells in the CNS.However, phenotypic and functional analyzes are limited. After the isolation of immune cells from the central nervous system of normal or diseased mice, more detailed phenotypes can be analyzed. With this method, T lymphocytes in the brain can be studied on a cellular basis, and the expression of various surface markers, cytokines, chemokine and transcription factors (eg, intracellular proteins) can be analyzed better. The protocol will be useful for future research to assess the phenotype and function of T lymphocytes in the brain during MS and EAE.

    Subscription Required. Please recommend JoVE to your librarian.

    News of world thyroidology | Sviridonova

    1. Yoshihara A., Noh J.Y., Ohye H. et al. Reference limits for serum thyrotropin in a Japanese population // Endocr. J. 2011. May 7

    2. Døssing H., Bennedbäk F.N., Hegedus L. Long term outcome following interstitial laser photocoagulation of benign cold thyroid nodules // Eur.J. Endocrinol. 2011. May 6

    3. Welch K.C., McHenry C.R. Total thyroidectomy: is morbidity higher for graves’ disease than nontoxic goiter? // J. Surg. Res. 2011. Apr 19

    4. Balta A.Z., Filiz A.I., Kurt Y. et al. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma // Med. Oncol. 2011 May 6

    5.Ahmed S., Van Gelder I.C., Wiesfeld A.C. et al. Determinants and outcome of amiodarone-associated thyroid dysfunction // Clin. Endocrinol. 2011. Apr 30

    6. Oppo A., Franceschi E., Atzeni F. et al. Effects of hyperthyroidism, hypothyroidism and thyroid autoimmunity on female sexual function // J. Endocrinol. Invest. 2011. Apr

    7.Gumez Q C.H., Vesga G J.F., Lowenstein De. et al. Mass screening for hypothyroidism in a cohort of HIV infect- ed patients in a Bogotb hospital, Colombia // Rev. Chilena. Infectol. 2011. V. 28 (1). P. 59–63.

    8. Kuppens S.M., Kooistra L., Wijnen H.A. et al. Neonatal thyroid screening results are related to gestational maternal thyroid function // Clin. Endocrinol. 2011. Apr

    9.Rotondi M., Cappelli C., Magri F. et al. Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome // Clin. Endocrinol. 2011. Mar

    10. Tagami T., Kimura H., Ohtani S. et al. Multi-center study on the prevalence of hypothyroidism in patients with hypercholesterolemia // Endocr. J. 2011

    11. Erbil Y., Ozbey N.C., Sari S. et al. Determinants of postoperative hypocalcemia in vitamin D-deficient Graves’ patients after total thyroidectomy // Am. J. Surg. 2011. V. 201 (5). P. 678-684.

    12.